Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 7, 2006, Pages 1586-1593

  Koenig, Wolfgang ^a   Twardella, Dorothee ^b   Brenner, Hermann ^b   Rothenbacher, Dietrich ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GERMAN CENTRE FOR RESEARCH ON AGEING   (Germany)

Author keywords

Cohort study; Coronary heart disease; Inflammation; Lipoprotein associated phospholipase A2 pathomechanism; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; BIOLOGICAL MARKER; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A(2); LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A(2); PHOSPHOLIPASE A;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; COVARIANCE; DISEASE MARKER; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEMODYNAMICS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; BLOOD; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; ENZYMOLOGY; KIDNEY; MIDDLE AGED; OSMOLARITY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; STRESS;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INFLAMMATION; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSMOLAR CONCENTRATION; PHOSPHOLIPASES A; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; STRESS;

EID: 33745965348     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000222983.73369.c8     Document Type: Article

References (33)

1. Macphee C, Benson GM, Shi Y, Zalewski A. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opin Investig Drugs. 2005;14:671-679.
2. Tselepis AD, Chapman JM. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atherosclerosis. 2002;Suppl 3:57-68.
3. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem. 1990;265:9682-9687.
4. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamaguchi K. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999;261:511-514.
5. Tarbet EB, Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, Prescott SM. Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem. 1991;266:16667-16673.
6. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909-2917.
7. Kolodgie F, Burke A, Taye A, Liu W, Sudhir K, Virmani R. Lipoprotein-associated phospholipase A2 is highly expressed in macrophages of coronary lesions prone to rupture. Circulation. 2004;110(suppl III):III-246. Abstract.
8. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413-419.
9. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res. 2002;43:256-263.
10. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479-487.
11. Kume N, Cybulsky MI, Gimbrone MA. Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992;90:1138-1144.
12. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85;2805-2809.
13. 2 inhibition-a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco. 2001;56:45-50.
14. Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Elliott RL, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Smith SA, Stansfield IG, Stanway SJ, Taylor MA, Theobald CJ, Whittaker CM. The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man. Bioorg Med Chem Lett. 2002;12:2603-2606.
15. 2. Bioorg Med Chem Lett. 2003;13:1067-1070.
16. 2 activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study. Circulation. 2004;110(suppl III):III-590 Abstract.
17. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148-1155.
18. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109:837-842.
19. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903-1908.
20. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570-575.
21. 2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137-144.
22. Hoogeveen RC, Ballantyne CM. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn. 2005;5:9-14.
23. Muche R, Ring C, Ziegler C. A SAS macro package for development and validation of prognostic and diagnostic models based on the logistic regressions model. Biom J. 2004;46(S1):154. Abstract.
24. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005;182:193-198.
25. 2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med. 2005;2:529-535.
26. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321-327.
27. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342-2348.
28. Rothenbacher D, Koenig W, Brenner H. Prognostic value of N-terminal pro-B natriuretic peptide levels: prospective cohort study in patients with stable coronary heart disease. Eur Heart J. 2005;26(Abstract Supplement):P1694. Abstract.
29. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40:437-445.
30. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
31. 2 and its association with cardiovascular outcomes in patients with acute coronary sSyndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation. 2006;[Epub ahead of print, March 14].
32. 2 and measures of extracoronary atherosclerosis: The Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006;26:631-636.
33. 2 mass and activity with calcified coronary plaque in young adults. The CARDIA study. Arterioscler Thromb Vasc Biol. 2005;25:216-221.